

Robust earnings growth underpinned by stronger-than-expected margin recovery

Dr. Sulaiman Al Habib reported a strong Q2-26, with net profit increasing 12.1% Y/Y (+31.7% Q/Q) to SAR 663mn, exceeding both our estimates of SAR 630mn by 5.1% and the consensus forecast of SAR 611.9mn by 8.2%. However, the strong operating performance was partially offset by less favorable below-operating-line items, limiting the net profit growth. Revenue grew a robust 18.4% Y/Y, supported by healthy growth in patient volumes across both inpatient and outpatient services. While gross margin remained below historical levels due to the continued ramp-up of recently commissioned hospitals, it recovered sharply on a sequential basis, reflecting normalization following the seasonal impact of Ramadan and Eid Al-Fitr. The stronger-than-expected recovery in profitability, coupled with improving hospital utilization and the recent six months' 19.4% correction in the share price, underpins our upgrade to a **"Overweight"** rating.

- **Sulaiman Al Habib posted a net profit** of SAR 663mn in Q2-26, reflecting a healthy 12.1% growth on a Y/Y basis, while also increasing by 31.7% sequentially. Despite gross margins Y/Y contraction by 100 bps, earnings increased significantly primarily on the strong revenue growth of 18.4%. Overall performance remained above expectations, with net profit coming in 5.1% above AJBC estimate of SAR 630mn and 8.2% ahead of the consensus forecast of SAR 611.9mn. However, stronger than expected operating performance was partially offset by less favorable below-operating-line items, limiting the net profit growth.
- **Revenues** increased by 18.4% Y/Y (+16.6% Q/Q) to SAR 4,006mn in Q2-26, exceeding our estimate of SAR 3,852mn by 4.0%. Growth was primarily driven by the Hospital segment, which accounts for c.77% of total revenue and expanded by 17.1% Y/Y, followed by the Pharmacies segment (+21.6% Y/Y; c.21% revenue share) and the Solutions segment (+46.7% Y/Y). The robust topline growth was mainly attributable to higher patient throughput across both inpatient (IPD) and outpatient (OPD) services during the quarter.
- **Gross profit** increased by 14.6% Y/Y to SAR 1,222mn in Q2-26 (+11.3% deviation to AJBC estimate of SAR 1,098mn). Although, gross margin contracted by 100 bps Y/Y to 30.5% (+200bps deviation to AJBC estimate of 28.5%). However, on sequential basis, gross margins expanded sharply by 268 bps after falling to one of the lowest levels in Q1-26 to 27.8%. This sharp sequential recovery in gross margins primarily reflects the normalization of operations following the amplified seasonal impact of Ramadan and Eid Al-Fitr in the previous quarter. Despite this recovery, gross margins remain below the historical range of 33-34%, as hospitals opened over the past two years continue to be in the ramp-up phase.
- **Operating profit** increased by 19.5% Y/Y and 31.1% Q/Q to SAR 770mn in Q2-26 (+10.0% deviation to AJBC estimate of SAR 701mn). Operating margin stood at 19.2% in Q2-26, up 17bps Y/Y (+212bps Q/Q) and 103bps above AJBC estimate of 18.2%. OPEX-to-sales normalizes by 117bps Y/Y to 11.3% as recently opened hospitals utilization kept on increasing.

AJBC view and valuation: Dr. Sulaiman Al Habib delivered a strong set of Q2-26 results, with earnings surpassing both our estimates and consensus expectations, supported by robust revenue growth and a stronger-than-anticipated recovery in gross margins. We believe the improving margin trajectory, coupled with continued ramp-up in recently commissioned hospitals, provides further upside to earnings over the medium term. Furthermore, following the recent 19.4% correction in the share price over the past six months, the current valuation offers an attractive entry point. Accordingly, we upgrade our rating on the stock to **"Overweight"** with a target price **SAR 270.7/share**.

Results Summary

SAR mn	Q2-25	Q1-26	Q2-26	Change Y/Y	Change Q/Q	Deviation from AJBC Estimates
Revenue	3,384	3,436	4,006	18.4%	16.6%	4.0%
Gross Profit	1,066	956	1,222	14.6%	27.8%	11.3%
Gross Margin	31.5%	27.8%	30.5%	-	-	-
EBIT	645	588	770	19.5%	31.1%	10.0%
Net Profit	591	503	663	12.1%	31.7%	5.1%
EPS	1.69	1.44	1.89	-	-	-

Source: Company Reports, Aljazira Capital Research

Recommendation	Overweight
Target Price (SAR)	270.7
Upside / (Downside)*	27.5%

Source: Tadawul *prices as of 23rd July, 2026

Key Financials

SARmn (unless specified)	FY23	FY24	FY25
Revenue	9,508	11,200	13,707
Growth %	14.4%	17.8%	22.4%
Gross Profit	3,270	3,744	4,207
EBIT	2,096	2,356	2,619
Net Profit	2,046	2,315	2,401
Growth %	23.9%	13.2%	3.7%
EPS	5.85	6.62	6.86
DPS	4.32	4.77	4.83

Source: Company reports, Aljazira Capital Research

Key Ratios

	FY23	FY24	FY25
GP Margin	34.3%	33.4%	30.6%
EBIT Margin	22.0%	21.0%	19.1%
Net Margin	21.5%	20.6%	17.5%
P/E (x)	48.6	42.4	41.3
P/B (x)	15.3	13.7	12.6
EV/EBITDA (x)	42.3	37.2	30.3
Div Yield (%)	1.5%	1.7%	1.7%

Source: Company reports, Aljazira Capital Research

Key Market Data

Market Cap(bn)	75.2
YTD%	-16.3%
52 week (High)/(Low)	281.2/210.1
Share Outstanding (mn)	350

Source: Company reports, Aljazira Capital Research

Price Performance



Senior Equity Analyst

Abdullah Umer

+966 54 796 3867

a.umer@aljaziracapital.com.sa

RESEARCH DIVISION

Director - Head of Sell-Side Research
Jassim Al-Jubran
+966 11 2256248
j.aljabran@aljaziracapital.com.sa

RESEARCH
DIVISION

Aljazira Capital, the investment arm of Bank Aljazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. Aljazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. Aljazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, Aljazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING
TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of securities, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. Some securities maybe, by nature, of low volume/trades, or may become so, unexpectedly in special circumstances, and this might increase the risk on the investor. Some fees might be levied on some investments in securities. Aljazira Capital, its employees, one or more of its board members, its affiliates, or its clients may have investments in the securities or assets referred to in this report. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.